Immunovant, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Immunovant, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2020 to Q3 2024.
  • Immunovant, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $45K, a 92.4% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $45K -$544K -92.4% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $66K -$816K -92.5% Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $133K -$1.04M -88.7% Mar 31, 2024 10-Q 2024-11-07
Q4 2023 $294K -$1.17M -79.8% Dec 31, 2023 10-Q 2024-02-12
Q3 2023 $589K -$1.15M -66.2% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $882K -$1.14M -56.4% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $1.17M -$1.13M -49.1% Mar 31, 2023 10-K 2024-05-29
Q4 2022 $1.46M -$993K -40.5% Dec 31, 2022 10-Q 2023-02-03
Q3 2022 $1.74M -$988K -36.2% Sep 30, 2022 10-Q 2022-11-04
Q2 2022 $2.02M -$984K -32.7% Jun 30, 2022 10-Q 2022-08-05
Q1 2022 $2.3M -$979K -29.8% Mar 31, 2022 10-K 2023-05-22
Q4 2021 $2.45M -$1.02M -29.3% Dec 31, 2021 10-Q 2022-02-04
Q3 2021 $2.73M -$762K -21.8% Sep 30, 2021 10-Q 2021-11-05
Q2 2021 $3.01M -$1.19M -28.4% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $3.28M +$3.28M Mar 31, 2021 10-K 2022-06-08
Q4 2020 $3.47M Dec 31, 2020 10-Q 2021-02-16
Q3 2020 $3.49M Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $4.2M Jun 30, 2020 10-K 2021-06-01
Q1 2020 $0 Mar 31, 2020 10-K 2021-06-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.